More on TAK
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $15.42 |
|
|||
| Open | $15.77 | ||||
| 52 Wk High | $0.55 | ||||
| 52 Wk Low | $0.55 | ||||
| Day High | $15.77 | ||||
| Day Low | $15.52 | ||||
| P/E | N/A | ||||
| EPS | $-0.20 | ||||
| Volume | 2,442,725 | ||||
- Form IRANNOTICE TAKEDA PHARMACEUTICAL
- Form 20-F TAKEDA PHARMACEUTICAL For: Mar 31
- Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY6,500 at Nomura/Instinet
- Goldman Sachs Reiterates Neutral Rating on Takeda Pharmaceutical (4502:JP) (TAK)
- New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
- Takeda's zasocitinib beats deucravacitinib in psoriasis study
- Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
- FDA accepts Takeda's application for pediatric ENTYVIO treatment
- U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 09
Entities mentioned with TAK
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- S1 | View Related Stories »
- Dividend | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
